Patent: 10,441,645
✉ Email this page to a colleague
Summary for Patent: 10,441,645
Title: | MSLN targeting DNA vaccine for cancer immunotherapy |
Abstract: | The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding Mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy. |
Inventor(s): | Springer; Marco (Wendlingen, DE), Lubenau; Heinz (Neustadt an der Weinstrasse, DE) |
Assignee: | VAXIMM GMBH (DE) |
Application Number: | 15/785,743 |
Patent Claims: | see list of patent claims |
Details for Patent 10,441,645
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Emergent Travel Health, Inc. | VIVOTIF | typhoid vaccine live oral ty21a | Capsule | 103123 | 12/15/1989 | ⤷ Try a Trial | 2033-12-18 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |